There aren't many cheap biotechs left out there, at least not among the higher-quality ideas. To be sure, arguing that Clovis Oncology (CLVS)
is undervalued after a better than 250% rise over the past year is
going to strike some as ridiculous. Even so, I believe the company has
multiple exciting pipeline opportunities that make this still a name
worth investigating further. Although I'm a little concerned that the
Street's expectations for clinical success are ahead of industry norms,
early-stage data have been quite encouraging.
Please click here to read more:
Clovis Oncology Has An Exciting Pipeline And A Reasonable Valuation
No comments:
Post a Comment